Mycolat (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycolat, is an antimetabolite presented as an oral formulation for oral use. It suppresses the immune system to help prevent organ transplant rejection and is sometimes employed off‑label for certain autoimmune disorders.

GNH USA supplies Mycolat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to European Union quality standards, provides regulatory‑approved batches for global distribution, and offers reliable logistics, batch traceability, and dedicated technical support.

Mycolat (mycophenolate mofetil) is used in immunosuppressive therapy to reduce lymphocyte‑mediated rejection.

Organ transplant rejection: prevents acute and chronic graft rejection by inhibiting lymphocyte proliferation. Kidney transplantation: lowers the incidence of rejection episodes in renal graft recipients. Autoimmune diseases (off‑label): may be employed to control severe lupus, vasculitis, or other immune‑mediated conditions when standard therapies are insufficient.

Mycolat may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache - Mild infections such as upper respiratory tract infections - Anemia or leukopenia - Elevated liver enzymes

Serious or Rare Side Effects: - Severe or opportunistic infections (e.g., cytomegalovirus, fungal infections) - Malignancies, including lymphoproliferative disorders - Progressive multifocal leukoencephalopathy (PML) - Significant bone marrow suppression leading to pancytopenia - Hepatic failure or severe hepatitis

Before initiating Mycolat, clinicians should assess baseline laboratory values and patient risk factors. - Blood monitoring: perform regular complete blood counts and renal function tests. - Infection risk: monitor for signs of bacterial, viral, or fungal infections. - Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant. - Live vaccines: do not administer live attenuated vaccines while on therapy. - Drug interactions: review concomitant medications for potential interactions, especially with azathioprine or strong CYP3A4 inhibitors. - Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Mycolat can interact with several medicines, requiring careful review.

Major Interactions (Avoid): - Azathioprine: combined use markedly increases bone‑marrow toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise mycophenolate levels and risk of severe adverse events.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Vaccines (non‑live): efficacy may be reduced; assess immune response when needed.